Co
Correvio (Advanz)
Vancouver CAFounded 2013100 employees
Private CapbiotechAcquiredCardiology
Platform: Brinavess
Market Cap
N/A
All Drugs
4
Clinical Trials
4
Failed / Terminated
0
FDA Approved
0
Drug Pipeline (4 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| COR-4726 | COR-4726 | Preclinical | 1 | PRMT5 | ThymomaGastric Ca | ||
| COR-8406 | COR-8406 | Phase 2 | 1 | ALK | SLEParkinson's | ||
| Lirabrutinib | COR-5821 | Phase 2/3 | 1 | CD47 | Breast Ca | ||
| COR-899 | COR-899 | Phase 2/3 | 1 | DLL3 | RBPAH |
Financial Documents
This company has been acquired — see parent company for financial filings.
Catalyst Events (4)